Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Visual Acuity and Intraretinal Fluid as Predictive Factors for Legal Blindness and Macular Atrophy in Neovascular AMD Eyes Treated with Anti-VEGF : A Swedish Real-World Study

Wickman, Isac LU ; Huzevkova, Ivana ; Schroeder, Marion LU ; Granstam, Elisabet ; Kjellström, Ulrika LU and Lövestam-Adrian, Monica LU (2026) In Clinical Ophthalmology 20.
Abstract

Purpose: Ocular coherence tomography (OCT) biomarkers have previously been able to predict low visual acuity (VA). The purpose of this study was to identify other OCT predictors for a final VA ≤35 and risk factors for macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD). Methods: This retrospective observational study included 107 treatment naïve nAMD eyes who initiated treatment and were followed for 3 years ± 2 months or until VA deterioration to or below 35 ETDRS letters. Eyes with final VA ≤35 letters (low VA group) were compared with those with a final VA >35 letters (maintenance group). Swedish Macula Register (SMR) data and OCT images were analyzed to identify risk factors for MA development... (More)

Purpose: Ocular coherence tomography (OCT) biomarkers have previously been able to predict low visual acuity (VA). The purpose of this study was to identify other OCT predictors for a final VA ≤35 and risk factors for macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD). Methods: This retrospective observational study included 107 treatment naïve nAMD eyes who initiated treatment and were followed for 3 years ± 2 months or until VA deterioration to or below 35 ETDRS letters. Eyes with final VA ≤35 letters (low VA group) were compared with those with a final VA >35 letters (maintenance group). Swedish Macula Register (SMR) data and OCT images were analyzed to identify risk factors for MA development and low VA. MA was defined according to the criteria for Complete Retinal Pigment Epithelium and Outer Retinal Atrophy (cRORA), which was based on OCT parameters. Results: Twenty eyes (19%) were presented with a final VA ≤35 ETDRS letters. Mean time from baseline to ≤35 ETDRS letters was 587.7 ± 330.4 days, with a mean 9.7 ± 5.3 injections during that period. Mean baseline VA in the maintenance group vs the low VA group were 65.4 ± 10.8 and 52.0 ± 10.6, respectively; p <0.001. Lower baseline VA was a predictor for low final VA. At baseline, 87% did not have MA on OCT. Among eyes with at least 1 OCT follow-up value in this group, 25% developed MA during the 3-year period. The presence of intraretinal fluid (IRF) at baseline was a predictor for MA development within 3 years in this subgroup. Conclusion: After 3 years, 19% had declined to VA ≤35 ETDRS letters. About 25% with ≥1 available OCT follow-ups developed MA. Lower baseline VA predicted a final VA ≤35 ETDRS letters in nAMD eyes. IRF at baseline predicted MA. The high prevalence of missing VA values emphasizes the importance of increasing the frequency of VA testing.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
anti-VEGF, macular atrophy, Swedish macula register
in
Clinical Ophthalmology
volume
20
article number
579968
publisher
Dove Medical Press Ltd.
external identifiers
  • scopus:105037548613
  • pmid:42088264
ISSN
1177-5467
DOI
10.2147/OPTH.S579968
language
English
LU publication?
yes
id
5449994d-027e-47c2-a842-221f03622a66
date added to LUP
2026-07-07 11:08:29
date last changed
2026-09-01 16:03:31
@article{5449994d-027e-47c2-a842-221f03622a66,
  abstract     = {{<p>Purpose: Ocular coherence tomography (OCT) biomarkers have previously been able to predict low visual acuity (VA). The purpose of this study was to identify other OCT predictors for a final VA ≤35 and risk factors for macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD). Methods: This retrospective observational study included 107 treatment naïve nAMD eyes who initiated treatment and were followed for 3 years ± 2 months or until VA deterioration to or below 35 ETDRS letters. Eyes with final VA ≤35 letters (low VA group) were compared with those with a final VA &gt;35 letters (maintenance group). Swedish Macula Register (SMR) data and OCT images were analyzed to identify risk factors for MA development and low VA. MA was defined according to the criteria for Complete Retinal Pigment Epithelium and Outer Retinal Atrophy (cRORA), which was based on OCT parameters. Results: Twenty eyes (19%) were presented with a final VA ≤35 ETDRS letters. Mean time from baseline to ≤35 ETDRS letters was 587.7 ± 330.4 days, with a mean 9.7 ± 5.3 injections during that period. Mean baseline VA in the maintenance group vs the low VA group were 65.4 ± 10.8 and 52.0 ± 10.6, respectively; p &lt;0.001. Lower baseline VA was a predictor for low final VA. At baseline, 87% did not have MA on OCT. Among eyes with at least 1 OCT follow-up value in this group, 25% developed MA during the 3-year period. The presence of intraretinal fluid (IRF) at baseline was a predictor for MA development within 3 years in this subgroup. Conclusion: After 3 years, 19% had declined to VA ≤35 ETDRS letters. About 25% with ≥1 available OCT follow-ups developed MA. Lower baseline VA predicted a final VA ≤35 ETDRS letters in nAMD eyes. IRF at baseline predicted MA. The high prevalence of missing VA values emphasizes the importance of increasing the frequency of VA testing.</p>}},
  author       = {{Wickman, Isac and Huzevkova, Ivana and Schroeder, Marion and Granstam, Elisabet and Kjellström, Ulrika and Lövestam-Adrian, Monica}},
  issn         = {{1177-5467}},
  keywords     = {{anti-VEGF; macular atrophy; Swedish macula register}},
  language     = {{eng}},
  publisher    = {{Dove Medical Press Ltd.}},
  series       = {{Clinical Ophthalmology}},
  title        = {{Visual Acuity and Intraretinal Fluid as Predictive Factors for Legal Blindness and Macular Atrophy in Neovascular AMD Eyes Treated with Anti-VEGF : A Swedish Real-World Study}},
  url          = {{http://dx.doi.org/10.2147/OPTH.S579968}},
  doi          = {{10.2147/OPTH.S579968}},
  volume       = {{20}},
  year         = {{2026}},
}